A carregar...
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the tumorigenesis and progression of this disease as well as in the resistance to radiotherapy (RT). While several anti-EGFR agents ha...
Na minha lista:
| Publicado no: | Front Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536039/ https://ncbi.nlm.nih.gov/pubmed/31165040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00383 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|